Aquilus Pharmaceuticals
PrivateLast Round
Accelerator
Sep 16, 2025
Total Funding Raised
$2.96M
Company Overview
Aquilus Pharmaceuticals operates in Healthcare & Life Sciences and is based in Winchester, Massachusetts. Its latest recorded funding round was an Accelerator round in September 2025.
Aquilus Pharmaceuticals is a biotechnology company that develops small molecule inhibitors for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and neuropathic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aquilus Pharmaceuticals Comparables
Compare Aquilus Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ProJenX, Inc. | 82% | |
| Algiax Pharmaceuticals | 79% | |
| Novaremed AG | 78% |
For institutional investors. Book with your work email.
Aquilus Pharmaceuticals Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Aquilus Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 157% MoM, reaching 992.
- Apr 3, 2026
Monthly visitors grew 2400% MoM, from 28 to 700.
For institutional investors. Book with your work email.
Aquilus Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aquilus Pharmaceuticals's valuation, stock price, and market status.
Is Aquilus Pharmaceuticals a public or private company?
Aquilus Pharmaceuticals is a private company.
What is the current stock price of Aquilus Pharmaceuticals?
Aquilus Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Aquilus Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aquilus Pharmaceuticals worth (valuation)?
Valuation information for Aquilus Pharmaceuticals is not publicly available.
Can I buy Aquilus Pharmaceuticals stock?
Aquilus Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aquilus Pharmaceuticals's last funding round?
Aquilus Pharmaceuticals's most recent funding round was Accelerator on September 16, 2025.
Who are the main investors in Aquilus Pharmaceuticals?
Key investors in Aquilus Pharmaceuticals include The ALS Association, National Institutes of Health (NIH).
Will Aquilus Pharmaceuticals IPO soon?
No public IPO plans have been announced for Aquilus Pharmaceuticals.
How can I track Aquilus Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Aquilus Pharmaceuticals's shares on secondary markets.